MedTrace Logo

Transcranial Magnetic Stimulation (TMS) for Suicidal Ideation

NCT01212848 · Status: UNKNOWN · Phase: PHASE3 · Type: INTERVENTIONAL · Enrollment: 42

Last updated 2013-04-26

No results posted yet for this study

Summary

The purpose of this study is to determine whether transcranial magnetic stimulation (TMS) is effective in the treatment of suicidal thinking in individuals with a depressive episode and either posttraumatic stress disorder (PTSD), history of mild traumatic brain injury (TBI), or both conditions.

Conditions

Interventions

DEVICE

Transcranial Magnetic Stimulation

Group 1: The treatment group will receive the following dose of repetitive TMS delivered over the left prefrontal cortex: 10 Hz, 120% Motor Threshold, 5 second pulse train, 10 second intertrain (IT) interval, 30 minutes of treatment, 6000 pulses per session; three sessions each day (18,000 stimuli) for three days for a total of 54,000 stimuli.

DEVICE

Transcranial Magnetic Stimulation - Sham Comparator

The control group will receive an identical dosing schedule of "sham" repetitive TMS over three days.

Sponsors & Collaborators

  • U.S. Army Medical Research and Development Command

    collaborator FED

  • Medical University of South Carolina

    collaborator OTHER

  • Ralph H. Johnson VA Medical Center

    collaborator FED

  • Walter Reed National Military Medical Center

    collaborator FED

  • University of California, San Diego

    collaborator OTHER

  • INTRuST, Post-Traumatic Stress Disorder - Traumatic Brain Injury Clinical Consortium

    lead OTHER

Principal Investigators

  • Mark S George, MD · Medical University of South Carolina

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-10-31
Primary Completion
2013-03-31
Completion
2013-10-31

Countries

  • United States

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01212848 on ClinicalTrials.gov